Rezpegaldesleukin · ZENITH AD-1
Nektar initiated ZENITH AD-1/2 in July 2026 and expects initial Phase 3 data in mid-2028. Phase 2 REZOLVE findings and the treatment-experienced AD-3 cohort are separate. rezpegaldesleukin — phase 3 study in Moderate-to-Severe Atopic Dermatitis. NCT07690371 lists US only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 and reduction ≥ 2 points from baseline at Week 24 as a primary outcome (Week 0 and Week 24). Registry status: recruiting.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Specify the exact future analysis/cohort and verify that it remains unpublished before creating any tradeable question.
- Registry design and recruitment status are not evidence of efficacy or regulatory approval.
- Primary completion is not a guaranteed topline publication or regulatory decision date.
- Registry primary completion: 2028-05 (estimated); verify independently before using it as a catalyst date.
- An active study record does not establish that its primary outcome is still unannounced. Review sponsor disclosures before promotion to a future catalyst.
- The registry lists 3 primary outcome measures. A market must explicitly specify which endpoint or conjunction resolves YES; this card highlights one measure only.
Primary evidence
Sponsor outlook: mid-2028 — no exact day
Potential outcome market
Will rezpegaldesleukin meet the prespecified primary endpoint in NCT07690371 by a listing deadline still to be specified?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.